Enhertu

View All

Pharma News for Merck, BMS, Sanofi, Juvena
Merck’s KEYTRUDA as Adjuvant Therapy for RCC Patients; BMS Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma for Multiple Myeloma; FDA Approves Dupixent for Eosinophilic Esophagitis; Juvena Receives FDA Orphan Drug Designation for JUV-161; European Commission Authorizes GSK’s Omjjara; ENHERTU Granted Priority Review in the US for for metastatic HER2-positive Solid Tumors

Merck’s KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With Renal Cell Cancer (RCC) at an Increased Risk of Recurrence Following Nephrectomy Merck, also known as MSD beyond the United States and Canada, has revealed findings from the Phase III KEYNOTE-564 trial, which a...

Find More

antibody-drug-conjugates-adcs-in-lung-cancer-treatment
A Quick Review of Antibody-Drug Conjugates (ADCs) in Lung Cancer: HER2, TROP-2, HER3, MET, and CEACAM5 ADC Advancements

Lung cancer remains the leading cause of cancer-related death in the United States. The American Cancer Society estimates 238,340 people will be diagnosed with lung cancer in 2023, with non-small cell lung cancer (NSCLC) accounting for the majority of cases (roughly 80% to 85%).The treatment paradigm of antibody-dr...

Find More

antibody-drug-conjugates-adcs-in-oncology
Antibody-drug Conjugates in Oncology: An Overview of the Current and Future Treatment Landscape

Antibody-drug conjugates (ADCs) are becoming more prominent in the cancer treatment market. Antibody-drug conjugates are one of the most rapidly increasing anticancer treatments. This approach uses a mAb attached to a cytotoxic payload via a chemical linker that is directed towards a target antigen expressed on the...

Find More

roches-her2-positive-breast-cancer-therapies
Roche’s HER2-Positive Breast Cancer Treatment Franchise

For most of the last century, breast cancer was categorized only by its location in the body; as a result, treatment results varied significantly. Patients with metastatic HER2+ breast cancer were traditionally treated with conventional chemotherapy regimens until trastuzumab became available. In September 1998, th...

Find More

top-10-oncology-drugs-launches-2023
Top 10 Expected Oncology Drug Launches in 2023

Cancer is the world’s second leading cause of death. Every year, 10 million people die from cancer. Cancer kills 70% of people in low-to-middle-income countries. Cancer is estimated to cost the global economy USD 1.16 trillion per year. Millions of lives could be saved annually by implementing resource-appropriate ...

Find More

latest-pharma-news-and-updates-for-eli-lilly-novartis-janssen-ipsen-kite
Eli Lilly’s Jaypirca Approval; Novartis’ Adakveo EMA Review; Janssen’s CARTITUDE-4 Study of CARVYKTI; Negative Review on Ipsen’s Palovarotene; Gilead Sciences and Kite’s Yescarta NICE Recommendations; Daiichi Sankyo and AstraZeneca’s Enhertu EU Approval

FDA Approves Eli Lilly’s Jaypirca for Relapsed Mantle Cell Lymphoma Eli Lilly has received FDA approval for Jaypirca, a non-covalent BTK inhibitor, in relapsed mantle cell lymphoma (MCL) patients who have relapsed after treatment with other drugs in the class. Adult MCL patients who have previously received at l...

Find More

enhertu-for-cancer-treatment-and-management
ENHERTU’s Journey in Cancer Treatment and Management

ENHERTU is an antibody-drug conjugate composed of an anti-HER2 antibody and a cytotoxic topoisomerase I inhibitor. Three components make up this ADC:  A topoisomerase inhibitor that is covalently linked to, Humanized anti-HER2 IgG1 monoclonal antibody (mAb) via, Tetrapeptide-based cleavable linker Rec...

Find More

Latest Pharma News for AstraZeneca and Bayer
FDA Approves AstraZeneca’s Enhertu; Bayer Wins FDA Approval for Prostate Cancer Therapy, Nubeqa; Gilead Sciences to Acquire MiroBio; AstraZeneca & Merck’s Lynparza Gets EU Approval; Pfizer to Acquire Global Blood Therapeutics; Sironax Raises USD 200 Million

FDA Approves AstraZeneca’s Enhertu as First Targeted Therapy for HER2-low Cancer Enhertu, developed by AstraZeneca and Daiichi Sankyo, has been approved by the FDA as the first targeted therapy for HER2-low breast cancer, a new subtype of the disease previously categorized as HER2-negative. It has the potential ...

Find More

recent-pharma-happenings-for-bluebird-pfizer-guardant-astrazeneca
Bluebird suspends gene therapy trials; Cortexyme tripped up by FDA hold; Guardant Health launches surveillance blood test; Enhertu scores approval

Bluebird suspends gene therapy trials after two sickle cell patients develop cancer Bluebird bio has stopped two clinical trials of its sickle cell disease gene therapy after participants developed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). During the pause, bluebird will assess whether the ...

Find More

Biohaven's Troriluzole; Daiichi/ AZ's Enhertu; Fujifilm Manufacturing Units
Biohaven’s Troriluzole Failure; Daiichi/ AZ’s Enhertu; Fujifilm & Manufacturing Spree; J&J’s Darzalex Faspro

Biohaven's Troriluzole Dwindles Again In Alzheimer’s After Anxiety  Biohaven Pharmaceuticals had put too much faith in its third-generation prodrug, Troriluzole. The company has tested the efficacy of the drug in more than one indication, including generalized anxiety disorder (GAD), obsessive-compulsive di...

Find More